These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 39318033)

  • 1. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.
    Scott SS; Greenlee AN; Matzko A; Stein M; Naughton MT; Zaramo TZ; Schwendeman EJ; Mohammad SJ; Diallo M; Revan R; Shimmin G; Tarun S; Ferrall J; Ho TH; Smith SA
    Heart Fail Clin; 2022 Jul; 18(3):425-442. PubMed ID: 35718417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.
    Vaidya T; Kamta J; Chaar M; Ande A; Ait-Oudhia S
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):401-418. PubMed ID: 29446053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity.
    Suleiman M; Al Najjar A; Zakaria ZZ; Ahmed R; Yalcin HC; Korashy HM; Uddin S; Riaz S; Abdulrahman N; Mraiche F
    J Cardiovasc Transl Res; 2024 Apr; 17(2):334-344. PubMed ID: 37725271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
    Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
    Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
    Singh AP; Umbarkar P; Tousif S; Lal H
    Int J Cardiol; 2020 Oct; 316():214-221. PubMed ID: 32470534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
    Sun K; Wang X; Zhang H; Lin G; Jiang R
    Cancer Control; 2024; 31():10732748241278039. PubMed ID: 39159918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity.
    Grabowska ME; Chun B; Moya R; Saucerman JJ
    J Mol Cell Cardiol; 2021 Jun; 155():66-77. PubMed ID: 33667419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy.
    Galvano A; Guarini A; Iacono F; Castiglia M; Rizzo S; Tarantini L; Gori S; Novo G; Bazan V; Russo A
    Expert Opin Drug Saf; 2019 Jun; 18(6):485-496. PubMed ID: 31062991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
    Yang B; Papoian T
    J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
    Binzaid AA; Baqal OJ; Soheib M; Al Nahedh M; Samarkandi HH; Aljurf M
    Gulf J Oncolog; 2021 Sep; 1(37):79-84. PubMed ID: 35152199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG
    Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies.
    Yang Y; Bu P
    Chem Biol Interact; 2016 Sep; 257():125-31. PubMed ID: 27531228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
    Shah RR; Morganroth J; Shah DR
    Drug Saf; 2013 May; 36(5):295-316. PubMed ID: 23620167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.
    Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A
    Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.
    Brown SA; Nhola L; Herrmann J
    Clin Pharmacol Ther; 2017 Jan; 101(1):65-80. PubMed ID: 27806435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.